Antimicrobial Susceptibility in Acute Myeloid Leukemia Patients in Erbil
Antibacterial Effectiveness Against Bacteria in AML Patients
DOI:
https://doi.org/10.21928/uhdjst.v9n2y2025.pp208-215Keywords:
Acute Myeloid Leukemia, Culture Media, Effectiveness, Antibiotic Susceptibility TestAbstract
Patients with acute myeloid leukemia (AML) demonstrate significant sensitivity to bacterial infections. Appropriate and efficient antibiotic treatment is essential to diminish the morbidity and mortality rate of the disease. This study aimed to determine the antibacterial susceptibility profile of bacterial isolates in AML patients in Erbil City. From August 2024 to January 2025, samples were obtained from the blood, gut, and urine of 40 AML patients at Nanakali Hospital in Erbil city. Among 40 cases of AML, 49 bacteria were isolated. Gram-negative bacteria (63.27%) were more prevalent than Gram-positive bacteria (36.73%). Most Gram-negative isolates were Escherichia coli (34.70%) and Klebsiella pneumoniae (16.43%), while Staphylococcus hominis (10.20%) was the most common Gram-positive. Against Gram-negative isolates, colistin (100%) showed the best antibacterial action, while vancomycin and imipenem both with percentage of 100% were most successful against Gram-positive isolates. Colistin, vancomycin, and imipenem had significant efficacy, confirming their application in therapy. Continuous surveillance of resistance is essential.
References
H. Döhner, A. H. Wei, F. R. Appelbaum, C. Craddock, C. D. DiNardo, H. Dombret, B. L. Ebert, P. Fenaux, L. A. Godley, R. P. Hasserjian, R. A. Larson, R. L. Levine, Y. Miyazaki, D. Niederwieser, G. Ossenkoppele, C. Röllig, J. Sierra, E. M. Stein, M. S. Tallman, H. F. Tien, J. Wang, A. Wierzbowska and B. Löwenberg. “Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN”. Blood, vol. 140, pp. 1345-1377, 2022.
E. H. Estey. “Acute myeloid leukemia: 2021 update on risk‐stratification and management”. American Journal of Hematology, vol. 95, pp. 1368-1398, 2020.
C. Gudiol and J. Carratalà. “Antibiotic resistance in cancer patients”. Expert Review of Anti-Infective Therapy, Vol. 12, pp. 1003-1016, 2014.
A. G. Freifeld, E. J. Bow, K. A. Sepkowitz, M. J. Boeckh, J. I. Ito, C. A. Mullen, I. I. Raad, K. V. Rolston, J. A. Young, J. R. Wingard and Infectious Diseases Society of America. “Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America”. Clinical Infectious Diseases, vol. 52, pp. e56-e93, 2011.
D. Mert, S. Ceken, G. Iskender, D. Iskender, A. Merdin, F. Duygu and M. Ertek, F. “Altuntas. Epidemiology and mortality in bacterial bloodstream infections in patients with hematologic malignancies”. The Journal of Infection in Developing Countries, vol. 13, pp. 727-735, 2019.
E. Tacconelli, E. Carrara, A. Savoldi, S. Harbarth, M. Mendelson, D. L. Monnet, C. Pulcini, G. Kahlmeter, J. Kluytmans, Y. Carmeli, M. Ouellette, K. Outterson, J. Patel, M. Cavaleri, E. M. Cox, C. R. Houchens, M. L. Grayson, P. Hansen, N. Singh, U. Theuretzbacher, N. Magrini and WHO Pathogens Priority List Working Group. “Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis”. The Lancet Infectious Diseases, vol. 18, pp. 318-327, 2018.
W. C. Reygaert. “An overview of the antimicrobial resistance mechanisms of bacteria”. AIMS Microbiology, vol. 4, p. 482, 2018.
E. M. Trecarichi, G. Giuliano, C. Cattaneo, S. Ballanti, M. Criscuolo, A. Candoni, F. Marchesi, M. Laurino, M. Dargenio, R. Fanci, M. Cefalo, M. Delia, A. Spolzino, L. Maracci, V. Bonuomo, A. Busca, M. I. D. Principe, R. Daffini, E. Simonetti, G. Dragonetti, M. E. Zannier, L. Pagano, M. Tumbarello and Hematologic Malignancies Associated Bloodstream Infections Surveillance (HEMABIS) Registry - Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne (SEIFEM) group, Italy. “Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: Updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey”. International Journal of Antimicrobial Agents, 61, pp. 106806, 2023.
H. Wisplinghoff, T. Bischoff and S. M. Tallent. “Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance stu. “dy”. Clinical Infectious Diseases, vol. 39, pp. 309-317, 2004.
E. M. Trecarichi, L. Pagano, B. Martino, A. Candoni, R. Di Blasi, G. Nadali, L. Fianchi, M. Delia, S. Sica, V. Perriello, A. Busca, F. Aversa, R. Fanci, L. Melillo, F. Lessi, M. I. Del Principe, C. Cattaneo, M. Tumbarello and Haematologic Malignancies Associated Bloodstream Infections Surveillance (HEMABIS) Registry - Sorveglianza Epidemiologica Infezioni Funginein Emopatie Maligne(SEIFEM) Group, Italy. “Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: Clinical impact of carbapenem resistance in a multicentre prospective survey”. American Journal of Hematology, vol. 91, pp. 1076-1081, 2016.
S. F. Nadeem, U. F. Gohar, S. F. Tahir, H. Mukhtar, S. Pornpukdeewattana, P. Nukthamna, A. M. Moula Ali, S. C. B. Bavisetty and S. Massa. “Antimicrobial resistance: More than 70 years of war between humans and bacteria”. Critical Reviews in Microbiology, 46, pp. 578-599, 2020.
R. Laxminarayan, A. Duse, C. Wattal, A. K. Zaidi, H. F. Wertheim, N. Sumpradit, E. Vlieghe, G. L. Hara, I. M. Gould, H. Goossens, C. Greko, A. D. So, M. Bigdeli, G. Tomson, W. Woodhouse, E. Ombaka, A. Q. Peralta, F. N. Qamar, F. Mir, S. Kariuki, Z. A. Bhutta, A. Coates, R. Bergstrom, G. D. Wright, E. D. Brown and O. Cars. “Antibiotic resistance-the need for global solutions”. The Lancet Infectious Diseases, vol. 13, pp. 1057-1098, 2013.
I. A. Naqid, A. A. Balatay, N. R. Hussein, H. A. Ahmed, K. A. Saeed and S. A. Abdi. “Bacterial strains and antimicrobial susceptibility patterns in male urinary tract infections in Duhok province, Iraq”. Middle East Journal of Rehabilitation and Health Studies, vol. 7, pp. e103529, 2020.
T. Vieceli and J. Rello. “Optimization of antimicrobial prescription in the hospital”. European Journal of Internal Medicine, vol. 106, pp. 39-44, 2022.
E. M. Trecarichi and M. Tumbarello. “Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: Current epidemiology and clinical impact”. Current Opinion in Infectious Diseases, 27, pp. 200-210, 2014.
S. Zhang, Q. Wang, Y. Ling and X. Hu. “Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer. BMC Cancer, vol. 15, p. 42, 2015.
T. Tängdén. “Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria”. Upsala Journal of Medical Sciences, vol. 119, pp. 149-153, 2014.
C. Costantini, E. Nunzi, A. Spolzino, M. Palmieri, G. Renga, T. Zelante, L. Englmaier, K. Coufalikova, Z. Spáčil, M. Borghi, M. M. Bellet, E. Acerbi, M. Puccetti, S. Giovagnoli, R. Spaccapelo, V. N. Talesa, G. Lomurno, F. Merli, L. Facchini, A. Spadea, L. Melillo, K. Codeluppi, F. Marchesi, G. Marchesini, D. Valente, G. Dragonetti, G. Nadali, L. Pagano, F. Aversa and L. Romani. “Pharyngeal microbial signatures are predictive of the risk of fungal pneumonia in hematologic patients”. Infection and Immunity, vol. 89, pp. e0010521, 2021.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Muna M. Najeeb, Sevan O. Majed
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
